Search details
1.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10419): 2295-2306, 2023 12 16.
Article
in English
| MEDLINE | ID: mdl-37931632
2.
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Oncologist
; 29(5): e690-e698, 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38377176
3.
The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Int J Mol Sci
; 25(9)2024 Apr 29.
Article
in English
| MEDLINE | ID: mdl-38732063
4.
Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
Oncologist
; 27(1): 7-12, 2022 02 03.
Article
in English
| MEDLINE | ID: mdl-35305107
5.
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network.
Eur J Cancer Care (Engl)
; 31(6): e13736, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-37039607
6.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Article
in English
| MEDLINE | ID: mdl-30280657
7.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
J Transl Med
; 19(1): 13, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33407605
8.
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
J Transl Med
; 19(1): 132, 2021 03 31.
Article
in English
| MEDLINE | ID: mdl-33789686
9.
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
BMC Cancer
; 21(1): 549, 2021 May 14.
Article
in English
| MEDLINE | ID: mdl-33985435
10.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32474768
11.
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy.
J Transl Med
; 18(1): 34, 2020 01 23.
Article
in English
| MEDLINE | ID: mdl-31973714
12.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Future Oncol
; 16(34): 2799-2808, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32854536
13.
Clinical trials and drug cost savings for Italian health service.
BMC Health Serv Res
; 20(1): 1089, 2020 Nov 26.
Article
in English
| MEDLINE | ID: mdl-33243262
14.
Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC.
Int J Mol Sci
; 21(14)2020 Jul 12.
Article
in English
| MEDLINE | ID: mdl-32664698
15.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31122901
16.
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Oncologist
; 24(11): e1165-e1171, 2019 11.
Article
in English
| MEDLINE | ID: mdl-30996007
17.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Future Oncol
; 15(25): 2905-2914, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31370698
18.
Pembrolizumab in lung cancer: current evidence and future perspectives.
Future Oncol
; 15(29): 3327-3336, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31432705
19.
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?
BMC Med
; 16(1): 24, 2018 02 16.
Article
in English
| MEDLINE | ID: mdl-29448944
20.
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future Oncol
; 14(27): 2861-2874, 2018 Nov.
Article
in English
| MEDLINE | ID: mdl-30336693